Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on...
Autori principali: | Watson, C, Bradley, J, Friend, P, Firth, J, Taylor, C, Bradley, JR, Smith, K, Thiru, S, Jamieson, N, Hale, G, Waldmann, H, Calne, R |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
2005
|
Documenti analoghi
Documenti analoghi
-
Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
di: Watson, C, et al.
Pubblicazione: (2004) -
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
di: Calne, R, et al.
Pubblicazione: (1999) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
di: Clatworthy, MR, et al.
Pubblicazione: (2009) -
CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
di: Friend, P, et al.
Pubblicazione: (1988) -
Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
di: Friend, P, et al.
Pubblicazione: (1991)